Spelling suggestions: "subject:"early atherosclerosis"" "subject:"early therosclerosis""
1 |
Remodelamento de partículas lipoprotéicas de alta densidade (HDL) e atividade antioxidante entre pacientes diabéticos e não diabéticos com doença aterosclerótica coronária.Amaral, Leonor Fernandes Teixeira January 2015 (has links)
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-07-26T12:55:35Z
No. of bitstreams: 1
Leonor Fernandes Teixeira Amaral Remodelamento...2015.pdf: 447268 bytes, checksum: f7454eb0efdd04147e5c7a0370bd8d82 (MD5) / Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-07-26T13:04:59Z (GMT) No. of bitstreams: 1
Leonor Fernandes Teixeira Amaral Remodelamento...2015.pdf: 447268 bytes, checksum: f7454eb0efdd04147e5c7a0370bd8d82 (MD5) / Made available in DSpace on 2016-07-26T13:04:59Z (GMT). No. of bitstreams: 1
Leonor Fernandes Teixeira Amaral Remodelamento...2015.pdf: 447268 bytes, checksum: f7454eb0efdd04147e5c7a0370bd8d82 (MD5)
Previous issue date: 2015-08-28 / Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / INTRODUÇÃO: as doenças cardiovasculares acometem milhares de pessoas no mundo,
sendo a doença aterosclerótica a de maior morbimortalidade. Além disso, a aterosclerose
pode manifestar-se precocemente dada a presença de dislipidemias, processos
inflamatórios e alterações metabólicas como a diabetes. OBJETIVO: avaliar se existem
diferenças no remodelamento da HDL e atividade antioxidante entre pacientes diabéticos
e não diabéticos com doença aterosclerótica. Ainda, identificar, quantificar e estimar
biomarcadores relacionados ao remodelamento de partículas lipoprotéicas e ao risco
cardiovascular em função da concentração de colesterol na HDL, colesterol livre total,
LDL-C, apoB, apoA-I, atividade da paraoxonase 1 (PON1), razões de risco como
TG/HDL-C, LDL-C/ApoB, HDL-C/apoA-I, PON1/apoA-I, apoA-I/ApoB e tamanho
estimado de partículas de HDL, LDL, glicemia, insulina e HbA1c. MÉTODOS: foram
selecionados por conveniência 69 pacientes do sexo masculino, entre 18 e 75 anos,
oriundos da enfermaria de cardiologia do Hospital Ana Neri, subdivididos em dois
subgrupos: diabéticos e não diabéticos, ambos, com doença aterosclerótica coronária.
Foram utilizadas metodologias enzimáticas, imunoturbidimétricas e nefelometricas nesse
estudo. RESULTADOS: dos achados da comparação direta entre os grupos apenas a
glicemia de jejum foi significativamente diferente (Teste t; p<0,05). Embora não
significante o valor do colesterol não esterificado (CL) foi, em média, quatro vezes maior
nos diabéticos quando comparado aos não diabéticos. A análise de correlação linear
mostrou achados importantes do ponto de vista fisiológico, como correlação positiva
entre CL e HDL-C (r=0,617; p<0,01083) e razão apoA-I/apoB e insulina (r=0,489;
p<0,02095) nos diabéticos, e correlação negativa entre PON1/apoA-I com CL (r=-0,499;
p<0,0065) e HDL-C com HbA1c (r=-0,444; p<0,0324) nos pacientes não diabéticos.
CONCLUSÃO: Os achados desse estudo mostram que o cálculo das razões utilizadas
para a análise de risco cardiovascular foram importantes indicadores quando
correlacionados com marcadores séricos sugestivos de risco cardiovascular na população
masculina diabética deste estudo. / Introduction: cardiovascular diseases affect thousands of people around the world, and
atherosclerotic disease is the one with the greatest morbidity and mortality. Furthermore,
atherosclerosis may manifest early by the presence of dyslipidemia, inflammatory
processes and metabolic disorders such as diabetes. Objective: to assess whether there
are differences between HDL remodeling and antioxidant activity from diabetic and nondiabetic
patients with coronary artery disease. Also, identify, quantify and evaluate
biomarkers related to lipoprotein particles remodeling and cardiovascular risk depending
on HDL cholesterol concentration, total free cholesterol, LDL-C, apoB, apoA-I,
paraoxonase activity 1 (PON1), and risk ratios like TG/HDL-C, LDL-C/ApoB, HDLC/
apoA-I, PON1/apoA-I, apoA-I/ApoB, HDL and LDL estimated particles size, glucose,
insulin and HbA1c. Methods: we selected by convenience 69 male patients between 18
and 75 years, from the Cardiology Unit of Hospital Ana Neri, they were subdivided into
two groups: diabetic and non-diabetic patients, both with coronary atherosclerosis. In
these study were used enzymatic, immunoturbidimetric and nephelometric
methodologies. Results: From the findings of the direct comparison between groups only
fasting glucose was significantly different (t test; p <0.05). Although not significant, the
value of non-esterified cholesterol (CL) was on average, four times higher in diabetics
when compared to non-diabetics. Linear correlation analysis showed significant findings,
from a physiological point of view, as positive correlation between CL and HDL-C (r =
0.617, p <0.01083) and apoA-I ratio/apoB and insulin (r = 0.489, p <0.02095) in diabetics,
and negative correlation between PON1/apoA-I with CL (r = -0.499; p <0.0065) and
HDL-C with HbA1c (r = -0.444; p <0.0324) in patients non-diabetic. Conclusion: the
findings shows that the calculated ratio´s used for cardiovascular risk analysis were
important indicators when correlated to serum markers suggestive of cardiovascular risk
in the study diabetic male population.
|
2 |
The Effects of Hyperglycemia on Early Endothelial Activation and Atherosclerotic Plaque Development / Hyperglycemia and the Endothelium in Early AtherosclerosisBallagh, Robert Alexander D January 2018 (has links)
A study of hyperglycemia and its effects on endothelial activation, macrophage recruitment, and atherosclerotic plaque development in mice. Hyperglycemic mice demonstrated greater VCAM but not ICAM expression along the endothelium, increased macrophage presence within the subendothelial space of these regions, and a greater volume of plaque in adulthood. / Cardiovascular disease is the leading cause of death in the world today. Atherosclerosis is the formation of plaque in the arteries and a major underlying cause of these fatalities. Type I and II diabetes are each strong independent risk factors for atherosclerosis. This study examines the effects of hyperglycemia on early atherosclerosis. Hyperglycemia did not promote atherosclerosis in the absence of hypercholesterolemia. Hyperglycemic mice demonstrated greater VCAM, but not ICAM, expression in regions of the endothelium susceptible to atherogenesis, prior to initiation of plaque development. Regions correlating to upregulation of VCAM exhibited a greater quantity of macrophages infiltrating the intima. This study suggests a unique and important role for VCAM in early atherosclerotic development and may explain the accelerated atherosclerotic plaque progression seen in hyperglycemic mice. This study also identifies VCAM as a potential target for the development of therapies to block or slow atherosclerotic plaque development in people with diabetes. / Thesis / Master of Science (MSc) / Cardiovascular disease is the leading cause of death in the world today. A major underlying cause of cardiovascular disease is atherosclerosis – a condition involving the thickening of the artery wall. Type I and II diabetes are each strong independent risk factors for atherosclerosis. The purpose of this study is to examine the effects of high blood glucose (hyperglycemia) on early events leading to atherosclerosis. This study found that hyperglycemia was not sufficient to promote atherosclerosis unless plasma cholesterol levels were also elevated. Hyperglycemia appeared to induce atherosclerosis by increasing the expression of factors responsible for recruiting white blood cells to the artery wall. This is consistent with the observation that hyperglycemic mice also had significantly more macrophages in the sites of plaque development. This study implicates one macrophage-recruitment factor in particular, vascular cell adhesion molecule (VCAM), as playing an important and unique role in the initiation of atherosclerosis by hyperglycemia. Therefore, VCAM is a possible target for the development of therapies to block or slow the development of atherosclerosis in individuals with diabetes.
|
Page generated in 0.061 seconds